Grand Rounds, Inc.

grandrounds.com

Grand Rounds’ vision is to create a path to great health and health care, for everyone, everywhere. Founded in 2011, the company provides an employer-based technology solution that connects members and their families to high-quality care. With Grand Rounds, employers get a personalized, high-performance network at scale, while their employees get the tools and support needed to navigate their care on their own terms. Named Rock Health’s 2018 Fastest Growing Company and second among Glassdoor’s 2016 Best Places to Work, Grand Rounds helps restore individual health and quality of life, and offers employers lower health care spend and higher employee productivity.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

BICYCLE THERAPEUTICS ANNOUNCES CONTINUED CLINICAL PROGRESS AND UPDATES TO MANAGEMENT TEAM

Bicycle Therapeutics | January 06, 2022

news image

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced continued progress in its ongoing Phase I/II clinical trials of BT8009, BT5528 and BT7480. “Last quarter, we reported interim clinical results from ongoing trials of two of our Bicycle toxin conjugates, BT8009 and BT5528, demonstrating preliminary anti-tumor activity in tw...

Read More

Medical

AXIM BIOTECH DEVELOPS RAPID QUANTITATIVE TEAR TEST FOR MMP-9, AN INFLAMMATORY BIOMARKER OF DRY EYE DISEASE

AXIM Biotech | March 10, 2022

news image

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has successfully developed a rapid quantitative tear test for MMP-9, an inflammatory biomarker for Dry Eye Disease. Dry Eye Disease, though widespread, is under-diagnosed, in part because symptoms do not always correlate with objective signs. It has a highly vari...

Read More

Industry Outlook

MAGENTA THERAPEUTICS AND DIANTHUS THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Globenewswire | May 04, 2023

news image

Magenta Therapeutics, Inc. and Dianthus Therapeutics, Inc. a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Dianthus’ pipeline of next-generation complement inhibitors, including DNTH103 currently in a Phase 1 clinical trial. Upo...

Read More

KANE BIOTECH WELCOMES RENOWNED CANADIAN VETERINARIAN, DR. JEAN GAUVIN, AS CHIEF VETERINARY OFFICER

BioSpace | February 20, 2020

news image

Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it has appointed Jean Gauvin, DVM, as its Chief Veterinary Officer (“CVO”), effective immediately. In the newly-created position of CVO, Dr. Gauvin will serve as a liaison between Kane Biotech and industry, guide the K...

Read More
news image

Cell and Gene Therapy

BICYCLE THERAPEUTICS ANNOUNCES CONTINUED CLINICAL PROGRESS AND UPDATES TO MANAGEMENT TEAM

Bicycle Therapeutics | January 06, 2022

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced continued progress in its ongoing Phase I/II clinical trials of BT8009, BT5528 and BT7480. “Last quarter, we reported interim clinical results from ongoing trials of two of our Bicycle toxin conjugates, BT8009 and BT5528, demonstrating preliminary anti-tumor activity in tw...

Read More
news image

Medical

AXIM BIOTECH DEVELOPS RAPID QUANTITATIVE TEAR TEST FOR MMP-9, AN INFLAMMATORY BIOMARKER OF DRY EYE DISEASE

AXIM Biotech | March 10, 2022

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has successfully developed a rapid quantitative tear test for MMP-9, an inflammatory biomarker for Dry Eye Disease. Dry Eye Disease, though widespread, is under-diagnosed, in part because symptoms do not always correlate with objective signs. It has a highly vari...

Read More
news image

Industry Outlook

MAGENTA THERAPEUTICS AND DIANTHUS THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Globenewswire | May 04, 2023

Magenta Therapeutics, Inc. and Dianthus Therapeutics, Inc. a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Dianthus’ pipeline of next-generation complement inhibitors, including DNTH103 currently in a Phase 1 clinical trial. Upo...

Read More
news image

KANE BIOTECH WELCOMES RENOWNED CANADIAN VETERINARIAN, DR. JEAN GAUVIN, AS CHIEF VETERINARY OFFICER

BioSpace | February 20, 2020

Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it has appointed Jean Gauvin, DVM, as its Chief Veterinary Officer (“CVO”), effective immediately. In the newly-created position of CVO, Dr. Gauvin will serve as a liaison between Kane Biotech and industry, guide the K...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us